

## ONLINE MUTATION REPORT

# Recurrent mutations in the *NF1* gene are common among neurofibromatosis type 1 patients

E Ars, H Kruyer, M Morell, E Pros, E Serra, A Ravella, X Estivill, C Lázaro

*J Med Genet* 2003;40:e82(<http://www.jmedgenet.com/cgi/content/full/40/6/e82>)

Neurofibromatosis type 1 (NF1) is one of the commonest autosomal dominant disorders in man, affecting 1 in 3500 people. Consensus clinical criteria were defined in 1987<sup>1</sup> and revised and updated in 1997.<sup>2</sup> Café au lait spots, axillary freckling, dermal neurofibromas, and Lisch nodules of the iris are the most common manifestations of this disorder. Most of the clinical symptoms of the disease are age dependent and considerable phenotypic variability has been described both between and within families.<sup>3,4</sup> This genetic disorder is caused by mutations in the *NF1* gene, one of the largest human genes, composed of 60 exons and spanning more than 300 kb of genomic DNA.<sup>5</sup> The determination of the *NF1* mutational spectrum has been complex owing to the large number of coding exons and the considerable mutational heterogeneity. Until recently, most diagnostic laboratories just offered linkage analysis for NF1 patients, which excluded diagnosis of the 50% of de novo cases. The use of techniques based on the analysis of *NF1* mRNA greatly facilitated the number of mutations identified and *NF1* screening efficiency, depicting a mutational *NF1* spectrum.<sup>6-8</sup> These studies highlighted the importance of splicing defects in molecular *NF1* pathology and, despite most patients bearing unique mutations, they suggested the recurrence of several mutations.

Here we present our experience with the direct analysis of the whole *NF1* coding region in 474 unrelated subjects suspected of having NF1. Mutations have been identified in 189 patients, 85 of them bearing recurrent mutations.

## MATERIALS AND METHODS

### Patients and families

Four hundred and seventy-four unrelated subjects suspected of having NF1 were analysed for mutations in the *NF1* gene. Included in these 474 cases are 80 NF1 patients studied previously.<sup>6</sup> Clinical data confirming NF1 diagnostic criteria were available in 201 (42%) of the subjects studied and in the remaining cases either no clinical data were provided or patients fulfilled only one diagnostic criterion. Patients with large deletions in the *NF1* gene, previously detected by loss of heterozygosity (LOH),<sup>9</sup> were excluded from this study. When available, blood samples of other family members were also obtained. All the participants were informed about the study and consent was obtained from all patients and their relatives.

### DNA/RNA extraction

DNA was extracted from peripheral blood by the "salting out" method.<sup>10</sup> Total RNA was extracted from peripheral blood lymphocytes using the Tripure isolation reagent (Boehringer Mannheim), according to the manufacturer's instructions.

### Mutation analysis of the *NF1* coding region by cDNA-SSCP/HD

Two to five µg of RNA were reverse transcribed using Superscript II reverse transcriptase (Invitrogen) and the entire *NF1* cDNA was amplified in 10 overlapping fragments ranging

in size from 636 to 1262 bp. These RT-PCR products were run in commercial 10% polyacrylamide gels (CleanGel DNA Analysis kit; Pharmacia Biosciences) and silver stained, in order to detect abnormal SSCP/HD patterns as previously described.<sup>6</sup> The abnormal products were characterised by using an automatic sequencer (ABI PRISM™ 377). Finally, all the alterations were characterised at the genomic level by amplification and direct sequencing of the specific exon bearing the sequence change identified in the cDNA.

### Statistical analysis

In order to determine whether mutations are equally distributed or not along the *NF1* gene, we used the  $\chi^2$  test to compare the observed frequency with respect to the expected one in every exon. Since mutations can be considered rare events, we assumed a Poisson distribution. We used SPSS software version 10.0 (SPSS Corp, Chicago, IL) and the test was evaluated using a significance level of 0.05.

## Key points

- The neurofibromatosis type 1 gene (*NF1*) has been described as bearing one of the highest mutation rates in the human genome. Half of the patients affected by NF1 are sporadic cases of the disease. Up to now it has been thought that most of these patients have private mutations which, in addition to the large size of the gene, has greatly hampered the definition of the mutational spectrum in NF1 patients.
- We present here our experience of four years using the cDNA-SSCP/HD approach for mutational screening of the whole *NF1* coding region. We have searched for *NF1* mutations in 474 unrelated subjects suspected of having NF1. We have identified 142 different *NF1* mutations in 189 patients. One hundred and four of these mutations have been found only once in this study, while the remaining 38 mutations have either been detected more than once in this study or have previously been published. Thus, we observed that 85 of 189 patients for which we identified a *NF1* mutation (45%) harbour a recurrent mutation.
- All detected alterations were characterised both at the genomic and RNA level. Considering the mutation effect in RNA processing, we have observed that 50% of patients harbour mutations that would lead to a recurrent alteration in mRNA. The detection of this high number of recurrent mutations could modify the routine genetic testing of the *NF1* gene by performing a search for these recurrent mutations as a first analytical step.

## RESULTS

Our centre has been offering mutational screening for the *NF1* gene since 1999 once the cDNA-SSCP/HD approach was optimised for the analysis of the whole *NF1* coding region in our laboratory.<sup>6</sup> By using this technology, we have studied 474 unrelated subjects suspected of having NF1. We have identified 189 independent *NF1* mutations in this sample comprising 142 different mutations (table 1). Eighty-five of these 189 unrelated patients (85/189, 45%) harbour 38 recurrent mutations (table 2) and the remaining 104 patients bear unique mutations (104/189, 55%). In all cases we have characterised both the DNA mutation and its effect at RNA level.

### Description of mutations at the DNA level

*NF1* mutations identified in the present study are distributed along the *NF1* gene (fig 1). However, there are eight exons/flanking introns in which mutations are represented more often (4b, 7, 10b, 13, 15, 20, 29, and 37), where 77 of the 189 mutations are located (41%), although they represent only 16% of the coding region. In order to test whether the mutations were equally distributed or not along the gene and assuming mutations as rare events, we have performed a  $\chi^2$  test. This test showed that there are areas of the *NF1* gene that have a greater tendency to accumulate mutations ( $p < 0.001$ ).

Regarding the classification of the 142 different DNA mutations, we observed that half of them are frameshift mutations, 31% affect the splicing consensus sequences, 9% are nonsense mutations, 8% are missense mutations, and only 2% represent amino acid deletions. Twenty-seven percent of these mutations were recurrent (38/142).

### Mutation effect on mRNA processing and the protein

When we studied the effect of these 142 mutations on mRNA processing, we obtained a different classification for the mutations. The percentage of mutations altering the correct splicing of the *NF1* pre-mRNA increased to 40% since, apart from the mutations affecting the consensus splicing sequences, we also found three frameshift, four nonsense, and five missense mutations that produced an aberrant *NF1* pre-mRNA splicing. If we consider this effect, 38% (54/142) of the identified mutations would lead to a recurrent effect on mRNA and are present in 50% of the patients. In relation to the putative effect of mutations at the protein level, only six mutations (4%) are not predicted to modify the size of neurofibromin. The remaining mutations would affect the neurofibromin size, 19% would produce an in frame protein with a slightly larger or smaller size than the authentic neurofibromin, and 77% of the mutations would lead to a truncated neurofibromin.

### Recurrent mutations

Eighty-five of the 189 independent NF1 patients in which the germline mutation has been identified (45%) harbour 38 different recurrent mutations (table 2). These mutations have been found in different unrelated patients of our set and/or have been previously published by other groups. In our population the most frequent mutations are two nonsense and two missense mutations, although interestingly all of them alter the correct mRNA splicing. The commonest mutation identified is 910C>T (R304X), which was found in seven independent patients. This mutation causes skipping of exon 7 and has been reported in several *NF1* mutational studies.<sup>7-11</sup> This mutation represents 8% of the recurrent mutations and 4% of the total of mutations identified. The commonly reported 6792C>A (Y2264X) mutation, which produces exon 37 skipping, has been identified in six patients, being the second most frequent recurrent mutation in our population. Two mutations were found in five unrelated patients (1885G>A and 5546G>A). Mutation 1885G>A inactivates the 3' consensus splice site and a cryptic 3' splice site is used instead,

producing the deletion of 41 nucleotides of exon 12b. Mutation 5546G>A causes the inactivation of the 5' splice site which leads to the skipping of exon 29.

### Identification of amino acid variants in the coding region

By using the cDNA-SSCP/HD assay we have detected four nucleotide substitutions that produce a change of amino acid in the affected position but which are not associated with the disease (table 1). Two changes are located in exon 29, R1825W (5473C>T) and R1809C (5425C>T), one in exon 4b, D176E (528T>A), and one in exon 21, N1229S (3686A>G). These changes were found in four sporadic NF1 patients and were also present in other unaffected relatives in their families. In the patient carrying the N1229S change, we characterised the causative *NF1* mutation (1466A>G, exon 10b); however, in the other three patients we were unable to detect any other nucleotide alteration. A priori these changes should be considered as rare variants owing to the fact that we have only identified them once in the sample of 474 independent patients analysed in this study. Variant D176E has previously been reported four times as a polymorphism in the German population,<sup>7,12</sup> while the other variants are described for the first time in this report.

### Phenotype-genotype correlation

No clear correlation has been found between a specific *NF1* mutation and a particular clinical feature. First of all, it has to be taken into account that in a large number of cases we have little clinical information owing to the fact that samples are referred to our laboratory from all over the country and from different clinical services. It is interesting to note that 66 of the studied patients were children with healthy parents aged from several months to less than 10 years. Most of these children have only café au lait spots and in some cases freckling was also reported. Although some of them do not fulfil the NF1 NIH consensus criteria, we have detected a *NF1* mutation in 20 of them (30%), confirming in these cases the affected status of the child. Considering the patients from whom clinical data were available, several findings were observed.

#### Café au lait spots and dermal neurofibromas

In general terms, although most patients present these age dependent traits, the quantitative information has been very poor in the vast majority of them. However, as we have previously described,<sup>6</sup> we have found the same mutation in patients of similar age with a very different number of lesions. This has been mainly seen in the cases with the most prevalent mutations (910C>T, 6792C>A, 1885G>A, and 5546G>A) in which it has been possible to compare a larger number of patients.

#### Plexiform neurofibromas

We have detected the *NF1* causing mutation in 15 of 25 unrelated patients in which the presence of plexiform neurofibromas was reported. The majority of these mutations will produce a truncated protein (13/15) and just two would produce a shorter in frame neurofibromin (IVS10b+1G>A and IVS18+5G>C). Considering these 15 patients, mutations 1466A>G and R681X are both present in two of them and two other patients have different mutations in exon 20 (3403-3404delTC and 3456-3459delACTC). The remaining patients harbour different recurrent (1541-1542delAG, 3822-3823delTC, R1947X, IVS45+790C>G) or unique (IVS10b+1G>A, 1756-1759delACTA, IVS17+2insT, IVS18+5G>C, IVS22+1G>C) mutations. Most of these mutations are outside the GRD although two are within it.

#### Scoliosis

The *NF1* mutation was characterised in nine of the 18 patients with scoliosis. Interestingly, four of these patients have the

**Table 1** One hundred and forty-two different *NF1* mutations and their effect on mRNA in 189 independent *NF1* patients

Mutation	E/I	mRNA level	Type/effect	Protein (aa)	No Pat (F/S)*
89-101del13	E 2	89-101del13	Frameshift	38 / TRUNC	1S
IVS2+1G/A	I 2	Skipping E 2	Splice	2770 / IF (-48)	1S
IVS3+4insG	I 3	Skipping E 3	Splice	2790 / IF (-28)	1S
347delA	E 4a	347delA	Frameshift	163 / TRUNC	1S
350T>G (I117S)	E 4a	350U>G	Missense	2818	1F
413-414insCT	E 4a	413-414insCU	Frameshift	164 / TRUNC	1F
446delA	E 4a	446delA	Frameshift	163 / TRUNC	1S
499-502delTGTT	E 4b	499-502delUGUU	Frameshift	175 / TRUNC	3 (3S)
527-528delAT	E 4b	527-528delAU	Frameshift	198 / TRUNC	1S
550delA	E 4b	550delA	Frameshift	189 / TRUNC	1S
580delC	E 4b	580delC	Frameshift	203 / TRUNC	1S
IVS4b+5G>A	I 4b	Inact 5' ss/skipping E 4b	Splice	163 / TRUNC	2 (1F, 1S)
686delA	E 5	686delA	Frameshift	279 / TRUNC	1S
717insTCCCACAG	E 5	717insUCCCACAG	Frameshift	282 / TRUNC	1S
723insA	E 5	723insA	Frameshift	243 / TRUNC	1S
878delA	E 6	878delA	Frameshift	293 / TRUNC	1S
IVS6+1G>A	I 6	Inact 5' ss/cryptic 5' ss/ 888ins60	Splice	2838 / IF (+20)	1F
910C>T (R304X)	E 7	Skipping E 7	Nonsense/splice	2760 / IF (-58)	7 (2F, 5S)
979delC>TT	E 7	979delC>UU	Frameshift	328 / TRUNC	1S
989insC	E 7	989insC	Frameshift	338 / TRUNC	1S
998insA	E 7	998insA	Frameshift	332 / TRUNC	1S
999delC	E 7	999delC	Frameshift	332 / TRUNC	1F
1019insT	E 7	1019insU	Frameshift	352 / TRUNC	1F
1019-1020delCT	E 7	1019-1020delCU	Frameshift	350 / TRUNC	1S
1021-1031del11	E 7	1021-1031del11	Frameshift	347 / TRUNC	1S
IVS7+1G>A	I 7	Skipping E 7	Splice	2760 / IF (-58)	1S
IVS8+1G>A	I 8	Inact 5' ss/skipping E 8	Splice	2777 / IF (-41)	1S
IVS8-1del15	I 8	Inact 3' ss/skipping E 9	Splice	2793 / IF (-25)	1F
IVS9+5G>C	I 9	Inact 5' ss/cryptic 5' ss/1260ins13	Splice	431 / TRUNC	1S
IVS9-2A>C	E 10a	1261del24	Splice	2810 / IF (-8)	1S
IVS10a-9T>A	I 10a	Inact 3' ss/cryptic 3' ss/1392insUUUUUAG	Splice	470 / TRUNC	1F
1399insA	E 10b	1399insA	Frameshift	468 / TRUNC	1F
1411A>T (K469X)	E 10b	1411A>U	Nonsense	468 / TRUNC	1S
1414delG	E 10b	1414delG	Frameshift	471 / TRUNC	1F
1465insT	E 10b	1465insU	Frameshift	489 / TRUNC	1S
1466A>G (Y489C)	E 10b	Cryptic 5' ss/1466del62	Missense/splice	488 / TRUNC	4 (1F, 3S)
IVS10b+1G>A	I 10b	Inact 5' ss/skipping E 10b	Splice	2773 / IF (-45)	1S
IVS10b+4delAGTA	I 10b	Inact 5' ss/skipping E 10b	Splice	2773 / IF (-45)	1F
IVS10b+5insA	I 10b	Inact 5' ss/skipping E 10b	Splice	2773 / IF (-45)	1S
1541-1542delAG	E 10c	1541-1542delAG	Frameshift	555 / TRUNC	4 (4S)
IVS10c-2A>G	I 10c	Inact 3' ss/skipping E 11	Splice	559 / TRUNC	1S
1677delT	E 11	1677delU	Frameshift	566 / TRUNC	1S
IVS11+3A>G	I 11	Inact 5' ss/skipping E 11	Splice	559 / TRUNC	2 (S)
IVS11-3C>G	I 11	Inact 3' ss/cryptic 3' ss/1721ins42	Splice	2832 / IF (+14)	1F
1756-1759delACTA	E 12a	1756-1759delACUA	Frameshift	602 / TRUNC	1S
1758-1759delTA	E 12a	1758-1759delUA	Frameshift	590 / TRUNC	1S
1797G>A (W599X)	E 12a	1797G>A	Nonsense	598 / TRUNC	1S
1885G>A (G629R)	E 12b	Inact 3' ss/cryptic 3' ss/1846-1887del41	Missense/splice	616 / TRUNC	5 (2F + 3S)
2041C>T (R681X)	E 13	2041C>U	Nonsense	680 / TRUNC	3 (2F, 1S)
2076insTGTA	E 13	2076insUGUAC	Frameshift	748 / TRUNC	1S
2077-2078delAT	E 13	2077-2078delAU	Frameshift	697 / TRUNC	1S
2173insT	E 13	2173insU	Frameshift	729 / TRUNC	1S
IVS13+2T>C	I 13	Inact 5' ss/skipping E 13	Splice	679 / TRUNC	1S
2310-2314delTGCA	E 14	2310-2314delUGCAG	Frameshift	772 / TRUNC	1S
2350T>C (W784R)	E 15	2350U>C	Missense	2818	1S
IVS15-12T>G	I 15	Cryptic 3' ss/2409ins11	Splice	823 / TRUNC	1S
IVS15-15A>G	I 15	Cryptic 3' ss/2409-2410ins14	Splice	822 / TRUNC	1F
IVS15-16A>G	I 15	Cryptic 3' ss/2409ins15	Splice	807 / TRUNC	4 (2F, 2S)
IVS15+2insT	I 15	Inact 5' ss/skipping E 15	Splice	2790 / IF (-28)	1F
2764G>A (G922S)	E 16	Cryptic 5' ss/2761del90	Missense/splice	2788 / IF (-30)	1F
IVS16+1G>A	I 16	Inact 5' ss/cryptic 5' ss/2617del233	Splice	876 / TRUNC	1S
IVS16-1delGGTTT	I 16	Inact 3' ss/skipping E 17	Splice	972 / TRUNC	1S
2942insGCTCTGA	E 17	2942insGCUCUGA	Frameshift	982 / TRUNC	1S
2970-2971delAA	E 17	2970-2971delAA	Frameshift	1018 / TRUNC	1S
2970-2972delAAT	E 17	2970-2972delAAU	Amino acid deletion	2817 / IF (-1)	1S
IVS17+2insT	I 17	Inact 5' ss/skipping E 17	Splice	972 / TRUNC	1S
IVS18+1G>T	I 18	Inact 5' ss/skipping E 18	Splice	2777 / IF (-41)	1S
IVS18+1G>A	I 18	Inact 5' ss/skipping E 18	Splice	2777 / IF (-41)	1S
IVS18+5G>C	I 18	Inact 5' ss/skipping E 18	Splice	2777 / IF (-41)	1F
IVS19a+1G>A	I 19a	Inact 5' ss/skipping E 19a	Splice	2790 / IF (-28)	1S
3214-3224del11	E 19b	Cryptic 5' ss/ 3211-3304del104	Frameshift/splice	1080 / TRUNC	1S
3239insT	E 19b	3239insU	Frameshift	1087 / TRUNC	1S
3277G>A (V1093M)	E 19b	Cryptic 5' ss/3275-3314del40	Missense/splice	1097 / TRUNC	1S
3394-3400delCGTGGCA	E 20	3394-3400delCGUGGCA	Frameshift	1138 / TRUNC	1S
3403-3404delTC	E 20	3403-3404delUC	Frameshift	1193 / TRUNC	1S
3419C>G (S1140X)	E 20	3419C>G	Nonsense	1139 / TRUNC	1S

Contd

Table 1 continued

Mutation	E/I	mRNA level	Type/effect	Protein (aa)	No Pat (F/S)*
3427C>T (H1140Y)	E 20	Cryptic 5' ss/3425del71	Missense/splice	1169 / TRUNC	1S
3456-3459delACTC	E 20	3456-3459delACUC	Frameshift	1155 / TRUNC	3 (3S)
3509delA	E 21	3509delA	Frameshift	1182 / TRUNC	1S
3525-3526delAA	E 21	3525-3526delAA	Frameshift	1192 / TRUNC	3 (2F, 1S)
3538-3543delATGGAA+insG	E 21	3538-3543delAUGGAA+insG	Frameshift	1191 / TRUNC	1S
3610C>T (R1204W)	E 21	3610C>U	Missense	2818	1S
3739-3742delTTTG	E 22	3739-3742delUUUG	Frameshift	1263 / TRUNC	1S
3759-3763delCTACC	E 22	3759-3763delCUACC	Frameshift	1260 / TRUNC	1F
3822-3823delCT	E 22	3822-3823delCU	Frameshift	1281 / TRUNC	1S
IVS22+1G>C	I 22	3844del26	Splice	1303 / TRUNC	1S
IVS23.1-2A>G	I 23.1	3975-3979delGUUAG	Splice	1330 / TRUNC	1F
4267A>G (K1423E)	E 24	4267A>G	Missense	2818	1S
4274T>C (L1425P)	E 25	4274U>C	Missense	2818	1F
4312-4314delGAA	E 25	4312-4314delGAA	Amino acid deletion	2817 / IF (-1)	1F
IVS25+1G>A	I 25	Inact 5' ss/skipping E 25	Splice	1426 / TRUNC	1S
4426delT	E 26	4426delU	Frameshift	1477 / TRUNC	1S
4493G>A (G1498E)	E 26	4493G>A	Missense	2818	1F
4537C>T (R1513X)	E 27a	4537C>U	Nonsense	1512 / TRUNC	1F
4568insC	E 27a	Inact 5' ss/skipping E 27a	Frameshift/splice	2769 / IF (-49)	1S
4614-4615delGT	E 27a	4614-4615delGU	Frameshift	1552 / TRUNC	1F
IVS27b+1del9	I 27b	Inact 5' ss/cryptic 5'/4704del69	Splice	2795 / IF (-23)	1F
4829del15	E 28	4829del15	Frameshift	1616 / TRUNC	1S
5094-5095delAG	E 28	5094-5095delAG	Frameshift	1699 / TRUNC	1F
5194insA	E 28	5194insA	Frameshift	1734 / TRUNC	1F
IVS28+1G>A	I 28	Inact 5' ss/cryptic 5'/5152del54	Splice	2800 / IF (-18)	1F
IVS28+5G>A	I 28	Inact 5' ss/cryptic 5'/5152del54	Splice	2800 / IF (-18)	1F
IVS28-2A>G	I 28	Inact 3' ss/skipping E 29	Splice	1739 / TRUNC	1S
5242C>T (R1748X)	E 29	5242C>U	Nonsense	1747 / TRUNC	1S
5303delA	E 29	5303delA	Frameshift	1771 / TRUNC	1S
5351insC	E 29	5351insC	Frameshift	1796 / TRUNC	1F
5460-5461delAC	E 29	5460-5461delAC	Frameshift	1838 / TRUNC	1F
5486insC	E 29	5486insC	Frameshift	1839 / TRUNC	1S
5546G>A (R1849Q)	E 29	Inact 5' ss/skipping E 29	Splice/missense	1739 / TRUNC	5 (2F, 3S)
IVS29+1G>A	I 29	Inact 5' ss/skipping E 29	Splice	1739 / TRUNC	1S
5617-5632del16	E 30	5617-5632del16	Frameshift	1897 / TRUNC	1S
5738insAT	E 30	5738insAU	Frameshift	1920 / TRUNC	1F
IVS30+332A>G	I 30	Cryptic 5' ss/5749ins177	Splice	1927 / TRUNC	3 (1F, 2S)
5839C>T (R1947X)	E 31	5839C>U	Nonsense	1946 / TRUNC	4 (1F, 3S)
5887delA	E 31	5887delA	Frameshift	1989 / TRUNC	1F
6395-6404del10	E 34	6395-6404del10	Frameshift	2174 / TRUNC	1F
6483C>G (Y2161X)	E 34	Skipping E 34	Nonsense/splice	2160 / TRUNC	1S
6579-6580insGCAT	E 35	6579-6580insGCAU	Frameshift	2221 / TRUNC	1S
6593insT	E 35	6593insU	Frameshift	2219 / TRUNC	1F
IVS35+2T>A	I 35	Inact 5' ss/skipping E 35	Splice	2198 / TRUNC	1S
6649delT	E 36	6649delU	Frameshift	2242 / TRUNC	1F
6724C>T (Q2242X)	E 36	Skipping E 36	Nonsense/splice	2258 / TRUNC	1S
IVS36+2T>A	I 36	Skipping E 36	Splice	2220 / TRUNC	1S
IVS36+3A>G	I 36	Skipping E 36	Splice	2220 / TRUNC	1F
6792C>A (Y2264X)	E 37	Skipping E 37	Nonsense/splice	2784 / IF (-34)	6 (2F, 4S)
6792insA	E 37	Skipping E 37	Frameshift/splice	2784 / IF (-34)	2 (2S)
IVS37+2T>G	I 37	Inact. 5' ss/skipping E 37	Splice	2784 / IF (-34)	1F
7096-7101delAACTTT	E 39	7096-7101delAACUUU	Amino acid deletion	2816 / IF (-2)	3 (2F, 1S)
7204-7205delCA	E 40	7204-7205delCA	Frameshift	2404 / TRUNC	1S
7267insA	E 41	7267insA	Frameshift	2425 / TRUNC	1F
7308insA	E 41	7308insA	Frameshift	2436 / TRUNC	1F
7337delC	E 41	7337delC	Frameshift	2466 / TRUNC	1F
7372delC	E 41	7372delC	Frameshift	2466 / TRUNC	1S
7702C>T (Q2568X)	E 44	7702C>U	Nonsense	2567 / TRUNC	1F
7719insA	E 44	7719insA	Frameshift	2573 / TRUNC	1S
7720delA	E 44	7720delA	Frameshift	2601 / TRUNC	1S
IVS44+1G>T	I 44	Inact 5' ss/skipping E 44	Splice	2567 / TRUNC	1S
IVS45+790C>G	I 45	7907ins70	Splice	2637 / TRUNC	2 (2S)
8040delT	E 46	8040delU	Frameshift	2716 / TRUNC	1F
8042insA	E 46	8042insA	Frameshift	2680 / TRUNC	1F
8047C>T (E2683X)	E 46	8047C>U	Nonsense	2682 / TRUNC	1F
8134-8135delAA	E 48	8134-8135delAA	Frameshift	2713 / TRUNC	1F
<i>Non-NF1 associated variants identified</i>					
528T>A (D176E)	E 4b	528T>A	Missense	2818	1S
3686A>G (N1229S)	E 21	3686A>G	Missense	2818	1S
5473C>T (R1825W)	E 29	5473C>U	Missense	2818	1S
5425C>T (R1809C)	E 29	5425C>U	Missense	2818	1S

\*Pat, patient; F, familial case, S, sporadic case.

E, exon; I, intron; inact, inactivation; TRUNC, truncated protein; IF, in frame; ss, splice site.

**Table 2** Thirty-eight *NF1* recurrent mutations in 85 independent *NF1* patients

Mutation	mRNA level	No Pat (F/S)*	References†
IVS4b+5G>A	Inact 5' ss / skipping E 4b	2 (1F, 1S)	–
499-502delTGTT	499-502delUGUU	3 (3S)	F, Ha, T
IVS6+1G>A	Inact 5' ss / cryptic 5' ss / 888ins60	1 (S)	F
910C>T (R304X)	Skipping E 7	7 (2F, 5S)	F, H, M,
1019-1020delICT	1019-1020delCU	1 (S)	F
IVS8+1G>A	Inact 5' ss / skipping E 8	1 (S)	F
1466A>G (Y489C)	Cryptic 5' ss / 1466del62	4 (1F, 3S)	F, M, O
1541-1542delAG	1541-1542delAG	4 (4S)	F, O
IVS11+3A>G	Inact 5' ss / skipping E 11	2 (S)	F
1756-1759delACTA	1756-1759delACUA	1 (S)	Pa
1885G>A (G629R)	Inact 3' ss / cryptic 3' ss / 1846-1887del41	5 (2F + 3S)	–
2041C>T (R681X)	2041C>U	3 (2F, 1S)	F
2350T>C (W2350R)	2350U>C	1 (S)	K
IVS15-16A>G	Cryptic 3' ss / 2409ins15	4 (2F, 2S)	–
2970-2972delAAT	2970-2972delAAU	1 (S)	F, M
IVS18+1G>A	Inact 5' ss / skipping E 18	1 (S)	P, K
3277G>A (V1093M)	Cryptic 5' ss / 3275-3314del40	1 (S)	M
3456-3459delACTC	3456-3459delACUC	3 (3S)	F, O
3525-3526delAA	3525-3526delAA	3 (2F, 1S)	F
3822-3823delCT	3822-3823delCU	1 (S)	F
IVS23.1-2A>G	3975-3979delGUUAG	1 (F)	F
4267A>G (K1423E)	4267A>G	1 (S)	K
4274T>C (L1425P)	4274U>C	1 (F)	F, Pe
4426delT	4426delU	1 (S)	Ho
4537C>T (R1513X)	4537C>U	1 (F)	F, M
5242C>T (R1748X)	5242C>U	1 (S)	F
5546G>A (R1849Q)	Inact 5' ss / skipping E 29	5 (2F, 3S)	F, M
IVS28-2A>G	Inact 3' ss / skipping E 29	1 (S)	G
IVS29+1G>A	Inact 5' ss / skipping E 29	1 (S)	F
IVS30+332A>G	Cryptic 5' ss / 5749ins177	3 (1F, 2S)	O, Per
5839C>T (R1947X)	5839C>U	4 (1F, 3S)	C, E, F, L, M
6792C>A (Y2264X)	Skipping E 37	6 (2F, 4S)	F, H, M, R
6792insA	Skipping E 37	2 (2S)	F
7096-7101delAACCTT	7096-7101delAACUUU	3 (2F, 1S)	M, A
7267insA	7267insA	1 (F)	O
7702C>T (Q2568X)	7702C>U	1 (F)	F
IVS45+790C>G	7907ins70	2 (2S)	–
8040delT	8040delU	1 (F)	Ho

\*Pat, patient; F, familial case; S, sporadic case; ss, splice site; inact, inactivation.

†This mutation has also been described by: A: Abernathy *et al*, 1994<sup>20</sup>; C: Cawthon *et al*, 1990<sup>21</sup>; E: Estivill *et al*, 1991<sup>22</sup>; F: Fashold *et al*, 2000<sup>7</sup>; G: Gironon-Boulandet *et al*, 2000<sup>23</sup>; H: Hoffmeyer *et al*, 1998<sup>11</sup>; Ha: Han *et al*, 2001<sup>24</sup>; Ho: reported by Horiuchi to the NNF Consortium; K: Kluwe *et al*, 2002<sup>25</sup>; L: Lázaro *et al*, 1995<sup>26</sup>; M: Messiaen *et al*, 2000<sup>8</sup>; O: Osborn and Upadhyaya 1999<sup>27</sup>; P: Purandare *et al*, 1995<sup>28</sup>; Pa: Park *et al*, 1998<sup>32</sup>; Pe: Peters *et al*, 1999<sup>29</sup>; Per: Perrin *et al*, 1996<sup>30</sup>; R: Robinson *et al*, 1995<sup>31</sup>; T: Toliat *et al*, 2000.<sup>12</sup>

same mutation in exon 10b (1466A>G), another has a mutation in intron 10b (IVS10b+1G>A), and the other four harbour different mutations (IVS7+1G>A, IVS30+322A>G, IVS37+2T>G, and IVS45+790C>G). None of these mutations is in the GRD.

### Optic glioma

Among 20 patients with optic glioma, we have detected the *NF1* mutation in 12. Most of these mutations are in the first exons of the *NF1* gene and three of them are located in exon 7 (1019insT, 989insC, and 998insA); all mutations are different and will produce truncated proteins. Apart from mutations in exon 7, the other mutations found were: 590delC, 1466A>G, IVS10a-9T>A, 1541-1542delAG, 1756-1759delACTA, 2173insT, 5351insC, 7204-7205delCA, and 7702C>T.

### Learning disabilities and mental retardation


Mental retardation has only been described in two patients harbouring mutations R681X and IVS30+322A>G. Among 16 patients described with learning disabilities we identified the *NF1* mutation in six. All of them carry different mutations that produce truncated proteins (989insC, IVS10c-2A>G, IVS15-16A>G, IVS23.1-2A>G, and 5303delA), except patient 99-135 who harbours a missense mutation in the GRD domain (4493G>A, G1498E).

### Detection of abnormal transcripts not caused by *NF1* mutations

The routine analysis of the *NF1* cDNA by SSCP/HD leads to the identification of several aberrant transcripts expressed in blood at a low proportion in comparison to the wild type transcript. When the genomic sequences corresponding to these transcripts were obtained, no DNA change was identified. The sequence of these abnormal transcripts suggests that they correspond to several previously described aberrant splice forms, such as the insertion of a cryptic exon (exon 4a-2),<sup>13, 14</sup> the skipping of some constitutional exons such as exon 20<sup>15</sup> or exon 43,<sup>15-17</sup> and also the presence of one of the alternative *NF1* isoforms consisting of the insertion of exon 23a.<sup>18</sup> Most of the samples showing these abnormal transcripts were samples sent to our laboratory from a long distance away and therefore the RNA was extracted several days after drawing of the blood.

### DISCUSSION

Mutational *NF1* screening for diagnostic purposes has been reported to be a difficult task owing to the size of the gene and to the absence of clear mutational hot spots. In the present study, we have observed that recurrent mutations are more common than previously described, being present in 45% of the patients in whom the *NF1* causative mutation has been identified. This percentage rises to 50% if we consider the



**Figure 1** Distribution of *NF1* mutations in 189 neurofibromatosis type 1 patients. Exons and introns are represented consecutively on the X axis and the number of mutations identified on the Y axis.

effect of mutations on mRNA processing. This result has important implications for the future design of *NF1* genetic tests and introduces the possibility of developing rapid tests focused on searching for these recurrent mutations as a first step in the routine diagnostic procedure. However, the recurrence rate calculated from the population studied here should be considered with caution since this population includes a large number of patients for whom either no clinical data were available or who did not fulfil the *NF1* diagnostic criteria. Therefore, an accurate final estimation of the mutation detection rate is not possible and, hence, a detection bias for certain mutations cannot be excluded.

Here we report the *NF1* mutational analysis of 474 unrelated subjects suspected of having *NF1* in whom we have detected 189 mutations. The mutations are scattered along the gene with some exons having a higher number of mutations, corresponding to exons harbouring recurrent mutations. We have found that 77 of the 189 mutations (41%) are located in just eight exons/flanking introns which represent only 16% of the coding region. The chi-square test gives statistical significance for a non-Poisson distribution of mutations, proving that they are over-represented in these exons ( $p < 0.001$ ).

Mutation 910C>T (R304X) in exon 7 is the commonest mutation detected in our population and this exon/flanking intron is the most mutated in our sample, in 15 out of 189 patients (8%). In addition both exons/flanking introns 10b and 29 are mutated in 11 patients each (6%). Our results agree with published reports on the absence of mutations in the alternative exons 9b, 23a, and 48a, but failed to find mutations in exons 23.2 and 27a which have previously been described as exons harbouring recurrent mutations.<sup>7,8</sup>

The predicted effect of the mutations on neurofibromin size is variable, although a great proportion of them will lead to the formation of a truncated protein. However, it is interesting to note that almost half of the mutations affecting RNA splicing would induce the formation of in frame transcripts resulting in a putative protein slightly shorter or longer than the authentic neurofibromin, but not truncated. We have identified six missense mutations and three deletions of amino acids (6%); this proportion is in agreement with data presented previously.<sup>7</sup>

Moreover, four polymorphic variants have been identified (D176E, N1229S, R1809C, and R1825W). These changes were found in sporadic patients and did not segregate with the disease since they are present in several unaffected relatives of the families. Variant N1229S is located in the GAP related domain and it is found in a patient in whom a *NF1* causative mutation has been identified (recurrent mutation 1466A>G).

This patient is a 27 year old woman with the typical clinical features of *NF1* including café au lait spots, neurofibromas, Lisch nodules, and optic glioma. On the other hand, we were unable to detect any other change in the other three patients. The patient with variant D176E is a 22 year old woman with a classical *NF1* presentation; this variant has previously been described as a polymorphism in four *NF1* German patients, thus it should also be considered a polymorphism in this patient.<sup>7,12</sup> The remaining two patients are children younger than 5 years with a clinical suspicion of *NF1* but without a firm diagnosis.

The lack of clinical information for most of the patients referred to our laboratory makes it impossible to provide final data about efficiency in *NF1* mutation detection. Although at first glance the mutation detection rate is lower than in our previous work,<sup>6</sup> it should be taken into account that in the pilot study only patients fulfilling *NF1* consensus diagnostic criteria were included. Since our centre offers direct genetic analysis of the whole *NF1* coding region all over Spain, not only classical *NF1* cases are referred but also clinically ambiguous patients, usually showing only one criterion of the disease. For instance, a considerable number of patients studied here (66 out of 474, 14%) are children aged from a few months to less than 10 years, most of them with only café au lait skin spots. These samples are mainly sent to our laboratory from paediatric services in order to confirm the probable diagnosis of *NF1*. In 20% of these patients we have detected the *NF1* mutation. For mutational screening by the cDNA-SSCP/HD approach we discarded patients bearing large *NF1* deletions detected by LOH or by FISH analysis, which represent around 5% of the *NF1* mutations in our population.<sup>9</sup> The approach used here has several limitations. Some single nucleotide mutations may be missed in the SSCP/HD analysis owing to the large size of the amplified fragments. Another important mechanism hampering mutation detection when using a RNA based approach is nonsense mediated mRNA decay (NMD), which could cause an under-representation of the mutated transcript.<sup>8,19</sup> Also, with this methodology, deletions involving several exons would be lost. Mechanisms reported in other genetic disorders such as large duplications or inversions cannot be ruled out as responsible for the remaining unidentified *NF1* mutations. Moreover, mutations located in the 5' or 3' untranslated regions should also be considered. Lastly, somatic mosaicism could be underlying some of the sporadic cases in which a mutation has not been identified in blood samples.

As previously described, special care has to be taken when an RNA approach is used for diagnostic purposes. We have

detected a large number of aberrant transcripts expressed in a low proportion compared to the normal one that could be misinterpreted as a result of the pathogenic mutation. However, most of them have been shown to be illegitimate transcripts produced by cold shock stress. This phenomenon is exacerbated when RNA is not extracted immediately after blood collection.<sup>13-16</sup> Unfortunately, 90% of samples are sent from other hospitals making it impossible to know how much time has elapsed after venepuncture. The establishment of short term cell cultures before RNA extraction and the addition of inhibiting substances to reduce NMD could be very useful in solving this problem and would improve the efficiency of the analysis.<sup>8</sup> With these possible sources of diagnostic error, to avoid mistakes in the final diagnosis, alterations detected in the cDNA must always be confirmed at the genomic level. This characterisation at both levels also provides interesting information, as we describe here, that some missense, nonsense, and frameshift mutations produce splicing alterations instead of the effect predicted for the mutation at the DNA level. These results have also to be taken into account in the design of functional studies using mutated protein models.

As has been described in published reports, it is very difficult clearly to identify any relationship between a mutation and a determined feature of the disease. In the work presented here, the establishment of any relation has been very limited because in a large number of cases we have not been able to obtain good clinical data on the patient(s). Moreover, the fact that café au lait spots and neurofibromas are age dependent quantitative traits has greatly hampered the possibility of making comparisons. However, several trends reported previously by our group<sup>6</sup> seem to be confirmed, such as the large number of mutations in exon 10b in patients with scoliosis and the fact that all patients with optic glioma harbour mutations that would produce a putative truncated neurofibromin. In contrast, it has been impossible to shed light on the putative relation of harbouring mutations producing altered in frame transcripts and a low number of neurofibromas. Nevertheless, the most probable explanation for the extreme clinical heterogeneity in NF1 is the role of modifier genes determining the expression of the clinical manifestations.<sup>3-4</sup> Another possibility could be that mutations altering the correct splicing of the *NF1* pre-mRNA could lead to variable levels of the abnormal transcript in different patients bearing the same mutation.<sup>6</sup> In order to elucidate the contribution of this event in NF1 aetiology, we are currently performing a study based on semi-quantitative PCR. Although our data are very preliminary, we have observed differences between patients in the percentage of mutated *NF1* transcripts versus wild type (E Pros, unpublished data).

In conclusion, the routine analysis of the *NF1* gene for diagnostic purposes shows that recurrent mutations are more common than previously expected, accounting for more than 40% of identified mutations. The new technological advances such as the microarray technology could be very useful for the genetic screening of the *NF1* gene; a chip harbouring the recurrent mutations would facilitate the molecular diagnosis of the disease. However, new approaches should be developed in order to identify mutations in the remaining patients. A combined approach such as the one described by Messiaen *et al*<sup>8</sup> based on a cascade of complementary techniques could be a good methodology although it is very laborious and expensive for routine analysis of hundreds of samples per year. Lastly, a method designed for the detection of multi-exon deletions should be considered in order to evaluate the role of this type of mutation in the molecular pathology of NF1.

## ACKNOWLEDGEMENTS

The first three authors contributed equally to this work. The authors wish to thank all the patients and family members who participated

in this study and all the clinicians for sending the family samples. We are very grateful to Rafael de Cid for the statistical calculation. This work was supported by grants of the Fondo de Investigaciones Sanitarias de la Seguridad Social (01/1475), the Ministerio de Ciencia y Tecnología (SAF2002-00573), and the Institut Català de la Salut.

## Authors' affiliations

**E Ars\***, **H Kruyer**, **M Morell†**, **E Pros**, **E Serra‡**, **X Estivill†**, **C Lázaro**, Centre de Genètica Mèdica i Molecular - IRO, Hospital Duran i Reynals, Barcelona, Spain

**A Ravella**, Servei de Dermatologia, Hospital de la Creu Roja, Barcelona, Spain

Correspondence to: Dr C Lázaro, Centre de Genètica Mèdica i Molecular - IRO, Hospital Duran i Reynals, Gran Via s/n, km 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Spain; clazaro@iro.es

\*Present address: Laboratoris, Fundació Puigvert, Barcelona, Spain

†Present address: Centre de Regulació Genòmica, Programa Gens i Malaltia, Parc de Recerca Biomèdica, Barcelona, Spain

‡Present address: The Molecular Sciences Institute, Berkeley, California, USA

## REFERENCES

- 1 NIH. NIH Consensus Development Conference Statement (1988). Neurofibromatosis. *Arch Neurol* 1988;**45**:575-8.
- 2 Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. *JAMA* 1997;**278**:51-7.
- 3 Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. *Am J Hum Genet* 1993;**53**:305-13.
- 4 Szudek J, Birch P, Riccardi VM, Evans DG, Friedman JM. Associations of clinical features in neurofibromatosis 1 (NF1). *Genet Epidemiol* 2000;**19**:429-39.
- 5 Li Y, O'Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, Neil S, Robertson M, White R, Viskochil D. Genomic organization of the neurofibromatosis 1 gene (NF1). *Genomics* 1995;**25**:9-18.
- 6 Ars E, Serra E, Garcia J, Kruyer H, Gaona A, Lazaro C, Estivill X. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1 (published erratum appears in *Hum Mol Genet* 2000;**9**:659). *Hum Mol Genet* 2000;**9**:237-47.
- 7 Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kucukcaylan N, Abdel-Nour M, Gewies A, Peters H, Kaufmann D, Buske A, Tinschert S, Nurnberg P. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. *Am J Hum Genet* 2000;**66**:790-818.
- 8 Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, Paepe AD. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. *Hum Mutat* 2000;**15**:541-55.
- 9 Lázaro C, Gaona A, Ravella A, Volpini V, Casals T, Fuentes JJ, Estivill X. Novel alleles, hemizygosity and deletions at an Alu-repeat within the neurofibromatosis type 1 (NF1) gene. *Hum Mol Genet* 1993;**2**:725-30.
- 10 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988;**16**:1215.
- 11 Hoffmeyer S, Nurnberg P, Ritter H, Fahsold R, Leistner W, Kaufmann D, Krone W. Nearby stop codons in exons of the neurofibromatosis type 1 gene are disparate splice effectors. *Am J Hum Genet* 1998;**62**:269-77.
- 12 Toliai MR, Erdogan F, Gewies A, Fahsold R, Buske A, Tinschert S, Nurnberg P. Analysis of the NF1 gene by temperature gradient gel electrophoresis reveals a high incidence of mutations in exon 4b. *Electrophoresis* 2000;**21**:541-4.
- 13 Ars E, Serra E, de la Luna S, Estivill X, Lazaro C. Cold shock induces the insertion of a cryptic exon in the neurofibromatosis type 1 (NF1) mRNA. *Nucleic Acids Res* 2000;**28**:1307-12.
- 14 Wimmer K, Eckart M, Rehder H, Fonatsch C. Illegitimate splicing of the NF1 gene in healthy individuals mimics mutation-induced splicing alterations in NF1 patients. *Hum Genet* 2000;**106**:311-13.
- 15 Thomson SA, Wallace MR. RT-PCR splicing analysis of the NF1 open reading frame. *Hum Genet* 2002;**110**:495-502.
- 16 Vandenbroucke I, Vandesompele J, De Paepe A, Messiaen L. Quantification of NF1 transcripts reveals novel highly expressed splice variants. *FEBS Lett* 2002;**522**:71-6.
- 17 Vandenbroucke II, Vandesompele J, Paepe AD, Messiaen L. Quantification of splice variants using real-time PCR. *Nucleic Acids Res* 2001;**29**:E68-8.
- 18 Andersen LB, Ballester R, Marchuk DA, Chang E, Gutmann DH, Saulino AM, Camonis J, Wigler M, Collins FS. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. *Mol Cell Biol* 1993;**13**:487-95.

- 19 **Hoffmeyer S**, Assum G, Griesser J, Kaufmann D, Nurnberg P, Krone W. On unequal allelic expression of the neurofibromin gene in neurofibromatosis type 1. *Hum Mol Genet* 1995;**4**:1267-72.
- 20 **Abernathy CR**, Colman SD, Kousseff BG, Wallace MR. Two NF1 mutations: frameshift in the GAP-related domain, and loss of two codons toward the 3' end of the gene. *Hum Mutat* 1994;**3**:347-52.
- 21 **Cawthon RM**, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O'Connell P, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations (published erratum appears in *Cell* 1990;**62**:following 608). *Cell* 1990;**62**:193-201.
- 22 **Estivill X**, Lazaro C, Casals T, Ravella A. Recurrence of a nonsense mutation in the NF1 gene causing classical neurofibromatosis type 1. *Hum Genet* 1991;**88**:185-8.
- 23 **Girodon-Boulandet EG**, Pantel J, Cazeneuve C, Gijn MV, Vidaud D, Lemay S, Martin J, Zeller J, Revuz J, Goossens M, Amselem S, Wolkenstein P. NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients with neurofibromatosis type 1. *Hum Mutat* 2000;**16**:274-5.
- 24 **Han SS**, Cooper DN, Upadhyaya MN. Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 (NF1) gene. *Hum Genet* 2001;**109**:487-97.
- 25 **Kluwe L**, Friedrich RE, Korf B, Fahsold R, Mautner VF. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas. *Hum Mutat* 2002;**19**:309.
- 26 **Lazaro C**, Kruyer H, Gaona A, Estivill X. Two further cases of mutation R1947X in the NF1 gene: screening for a relatively common recurrent mutation. *Hum Genet* 1995;**96**:361-3.
- 27 **Osborn MJ**, Upadhyaya M. Evaluation of the protein truncation test and mutation detection in the NF1 gene: mutational analysis of 15 known and 40 unknown mutations. *Hum Genet* 1999;**105**:327-32.
- 28 **Purandare SM**, Lanyon WG, Arngrimsson R, Connor JM. Characterisation of a novel splice donor mutation affecting position +1 in intron 18 of the NF-1 gene. *Hum Mol Genet* 1995;**4**:767-8.
- 29 **Peters H**, Luder A, Harder A, Schuelke M, Tinschert S. Mutation screening of neurofibromatosis type 1 (NF1) exons 28 and 29 with single strand conformation polymorphism (SSCP): five novel mutations, one recurrent transition and two polymorphisms in a panel of 118 unrelated NF1 patients. *Hum Mutat* 1999;**13**:258.
- 30 **Perrin G**, Morris MA, Antonarakis SE, Boltshauser E, Hutter P. Two novel mutations affecting mRNA splicing of the neurofibromatosis type 1 (NF1) gene. *Hum Mutat* 1996;**7**:172-5.
- 31 **Robinson PN**, Boddlich A, Peters H, Tinschert S, Buske A, Kaufmann D, Nurnberg P. Two recurrent nonsense mutations and a 4 bp deletion in a quasi-symmetric element in exon 37 of the NF1 gene. *Hum Genet* 1995;**96**:95-8.
- 32 **Park VM**, Pivnick EK. Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients. *J Med Genet* 1998;**35**:813-20.